Australia
Extended Abstract
Clinical Cardiology Congress 2020: An Audit of Glucose Lowering Therapies In Patients With Type 2 Diabetes And Hospitalisation for Heart Failure - Meor Azraai - The Royal Melbourne Hospital & NorthWestern Mental Health.
Author(s): Meor Azraai
Background: The CSANZ Heart Failure (HF) guidelines state that sodium-glucose co-transporter-2 inhibitors (SGLT2i) are the preferred second line agent in patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease to reduce CV events and HF hospitalisation.
Aim: To review glucose lowering therapies in patients with T2DM who had been hospitalised with HF at Austin Health, and the percentage of patients .. Read More»
Research and Reports in Medical Sciences received 13 citations as per Google Scholar report